Next-generation triple agonist (GLP-1 / GIP / glucagon) producing the largest weight-loss results seen in trials to date.
Retatrutide is an investigational once-weekly peptide that activates three metabolic receptors at once — GLP-1, GIP, and glucagon. The first two (the incretin receptors) suppress appetite and improve how the body handles blood sugar; the third, glucagon, adds an energy-expenditure component that increases how many calories the body burns at rest.
That third receptor is what sets retatrutide apart from semaglutide and tirzepatide. In its phase 2 trial, participants on the highest dose lost an average of roughly 24% of body weight over 48 weeks — the largest reduction reported for any pharmacological agent to date, with the weight-loss curve still trending downward when the study ended.
It is still investigational and has not completed phase 3 trials, so long-term safety and the final approved dosing are not yet established. The side-effect profile so far mirrors other incretin drugs — mostly dose-dependent nausea, vomiting, and other GI effects that ease with slow titration.
The deepest weight reduction seen in incretin trials, driven by appetite suppression plus increased energy expenditure from the glucagon arm.
Phase 2 RCT: ~24% mean weight loss at 48 weeks (highest dose)
Improves insulin sensitivity and blood-sugar handling alongside fat loss.
Phase 2 data in type 2 diabetes shows strong HbA1c reduction
The glucagon component appears to meaningfully reduce hepatic fat, of interest for fatty liver disease.
Early data shows large reductions in liver fat content
We rate every peptide honestly across four dimensions — and tell you what it's not.
Evidence Profile
Phase 2 data shows the largest weight loss of any incretin drug to date, but it is still investigational — phase 3 and long-term safety are pending.
Promising but early. Strong animal data and/or small/preliminary human studies, not yet confirmed in robust trials.
Controlled trials & clinical data in people
Positive phase 2 RCTs for obesity and type 2 diabetes; phase 3 trials ongoing, not yet complete.
Preclinical results in animal models
Robust preclinical metabolic data underpinning the triple-agonist design.
How plausibly it works at a biological level
Well-understood GLP-1 / GIP / glucagon receptor pharmacology.
Depth of documented safety in humans
Side-effect profile consistent with incretin class so far; long-term and large-scale safety still accumulating.
Men with substantial weight to lose, or those who have plateaued on a GLP-1/GIP drug and want a stronger metabolic effect
Start at the lowest dose and titrate up slowly over months to manage nausea. Prioritize protein and resistance training to protect lean mass during rapid loss. Investigational — source and long-term safety are real considerations.
Women seeking significant, sustained weight loss under a careful titration plan
Must not be used while pregnant, trying to conceive, or breastfeeding — use reliable contraception. Slow titration is especially important to keep GI effects tolerable. Watch for muscle and bone loss with very rapid weight reduction.
Effective for women but must not be used while pregnant, trying to conceive, or breastfeeding. Use reliable contraception throughout.
This section is always free and never locked.
Do not use with a personal or family history of medullary thyroid carcinoma or MEN 2.
Stop immediately and seek care for signs of pancreatitis (severe, persistent abdominal pain).
Titrate slowly to limit nausea, vomiting, and other GI effects.
Investigational compound — long-term human safety data is still emerging.
Prioritize protein and resistance training to preserve lean mass during rapid weight loss.
The effects most commonly reported with Retatrutide, when they tend to show up, and how to manage them.
Eat smaller, lower-fat meals; titrate slowly; it usually fades within 1–2 weeks at a stable dose.
Hydrate well, add fiber, stay active. Tell your clinician if severe or persistent.
Prioritize protein and don't under-eat — rapid loss can cost muscle. Lift weights.
Rotate sites; let alcohol dry fully before injecting.
Stop immediately and seek medical care — this is a red-flag symptom.
Individual responses vary. Stop and consult a clinician for severe, persistent, or unexpected reactions.
14 steps with photos, pro tips, and a dosing calculator.
Unlock Full Guide7 days free. Then $24/month.
████████ ████
████████ ████
████████ ████
Dosing info requires Core or Pro
Unlock DosingAlways free. Never locked.
A preview of the member outcomes dashboard. Real, anonymized Retatrutide results populate here as the community logs data.
See aggregated results from real users — benefit ratings, common goals, side effect frequency, and more.
Unlock with Core or ProGet the complete step-by-step guide, personalized dosing, and daily tracking.
View Full GuidePepCompass provides educational information only. Nothing on this platform constitutes medical advice, diagnosis, or treatment. All content is for informational and research purposes only. Always consult a licensed healthcare provider before starting any peptide protocol. Individual results vary.